Abstract
The overall prognosis for cancers of unknown primary (CUP) is poor, median overall survival (OS) being 6-12 months. We evaluated our multicentric retrospective experience for CUP administered docetaxel and cisplatin combination therapy. A total of 29 patients that were pathologically confirmed subtypes of CUP were included in the study. The combination of docetaxel (75 mg/m2, day 1) and cisplatin (75 mg/m2, day 1) was performed as a first line regimen every 21 days. The median age was 51 (range: 27-68). Some 17 patients had multimetastatic disease on the inital diagnosis. Histopathological diagnoses were well-moderate differentiated adenocarcinoma (51.7%), undifferentiated carcinoma (27.6%), squamous cell cancer (13.8%), mucoepidermoid carcinoma (3.4%) and neuroendocrine differentiated carcinoma (3.4%). Median number of cycles was 3 (range: 1-6). Objective response rate was 37.9% and clinical benefit was 58.6%. Median progression free survival (PFS) and overall survival (OS) were 6 months (range: 4.3-7.7 months) and 16 months (range: 8.1-30.9 months), respectively. Fourteen patients (60.8%) were treated in a second line setting. There was no treatment related death. Most common toxicities were nausia-vomiting (44.6%) and fatigue (34.7%), serious cases (grade 3/4) suffering nausia-vomiting (10.3%), neutropenia (13.8%) and febrile neutropenia (n=1). The combination of cisplatin and docetaxel is an effective regimen for selected patients with CUP.
Highlights
Cancer of unknown primary (CUP) accounts for 2-10% of all malignancies and accepted as metastatic cancer (Fizzazi et al, 2011; Pavlidis et al, 2012; Greco et al, 2012)
We evaluated our multicentric retrospective experience for cancers of unknown primary (CUP) administered docetaxel and cisplatin combination therapy
Here-in, we evaluated our multicentric retrospective experience for CUP administering docetaxel and cisplatin in combination therapy
Summary
Cancer of unknown primary (CUP) accounts for 2-10% of all malignancies and accepted as metastatic cancer (Fizzazi et al, 2011; Pavlidis et al, 2012; Greco et al, 2012). Pathologic diagnosis is adenocarcinoma and the disease is on the multimetastatic sites. The prognosis of CUP is poor, response rate (RR) is 20-35%, median overall survival (OS) is 6-12 months and one year OS is 15-35% (Fizzazi et al, 2011; Greco et al, 2012; Pavlidis et al, 2012). The overall prognosis for cancers of unknown primary (CUP) is poor, median overall survival (OS) being 6-12 months. We evaluated our multicentric retrospective experience for CUP administered docetaxel and cisplatin combination therapy. The combination of docetaxel (75 mg/m2, day 1) and cisplatin (75 mg/m2, day 1) was performed as a first line regimen every 21 days. Conclusion: The combination of cisplatin and docetaxel is an effective regimen for selected patients with CUP
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
